---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-22-000050"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:53:53.742712+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech Q2 net loss widens to $28.1M; BLA filed for B-VEC, KB407 IND accepted

## Summary
- Q2 net loss $28.1M ($1.10/share) vs $16.4M loss YoY; cash $438.5M.
- Filed BLA for B-VEC (DEB therapy) with FDA on June 22, 2022.
- FDA accepted IND for KB407 (cystic fibrosis); Phase 1 trials expected 2H 2022.
- R&D expense $10.9M, G&A $17.9M; losses reflect increased commercial prep.
- Pipeline: KB105 dosing to resume 2H 2022; KB104 IND later 2022; KB301 Phase 2 in Q4 2022/Q1 2023.

## SEC filing metadata
- accession: 0001711279-22-000050
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127922000050/0001711279-22-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127922000050/krys-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-22-000050
- JSON: https://secwatch.observer/filing/0001711279-22-000050.json
- Plain text: https://secwatch.observer/filing/0001711279-22-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.